Zealand Pharma to participate in upcoming healthcare investor conferences in May and June 2025

Press release – No. 8 / 2025

Zealand Pharma to participate in upcoming healthcare investor conferences in May and June 2025

Copenhagen, Denmark, May 12, 2025 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that the company will participate in the following healthcare investor conferences in May and June 2025:

• Bank of America Global Healthcare Conference, May 13-15 in Las Vegas

David Kendall, Executive Vice President and Chief Medical Officer, will present on Wednesday, May 14 at 8:00am PT (5:00pm CET).

A live audio webcast of the presentation will be available at https://bofa.veracast.com/webcasts/bofa/healthcare2025/id0V27z5.cfm.

• Berenberg European Conference, May 20-22 in New York

Adam Steensberg, President and Chief Executive Officer, to host investor meetings on Tuesday, May 20.

• Barclays European Leadership Conference, May 22 in London

David Kendall, Executive Vice President and Chief Medical Officer to participate in a panel discussion about obesity on Thursday, May 22 at 11:30am UKT (12:30pm CET). The panel will not be webcast.  

• Jefferies Global Healthcare Conference, June 3-5 in New York

Anna Krassowska, Vice President, Investor Relations & Corporate Communications to participate in a fireside chat on Thursday, June 5 at 11:40am ET (5:40pm CET). The fireside chat will not be webcast.

• Goldman Sachs Annual Global Healthcare Conference, June 9-11 in Miami

Adam Steensberg, President and Chief Executive Officer, to participate in fireside chat on Wednesday, June 11 at 4:00pm ET (10:00pm CET).

A webcast of the fireside chat will be available at https://www.zealandpharma.com/events/ in the coming weeks, where replays of all webcasts are also archived.

About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand Pharma have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products.

Zealand Pharma was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. For more information about Zealand Pharma’s business and activities, please visit www.zealandpharma.com.

Contacts
Adam Lange (Investors)
Vice President, Investor Relations
[e-mail]

Neshat Ahmadi (Investors)
Investor Relations Manager
[e-mail]

Anna Krassowska, PhD (Investor and Media)
Vice President, Investor Relations & Corporate Communications
[e-mail]